Roche Holding AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
Phase 3
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Drug: Rituximab IVDrug: Rituximab SCDrug: CyclophosphamideDrug: DoxorubicinDrug: VincristineDrug: Prednisone/Prednisolone
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 410
- Registration Number
- NCT01200758
- Locations
- π¨π΄
Fundacion Cardioinfantil, Bogota, Colombia
π²π½Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre, Chihuahua, Mexico
π¨π΄Centro Medico Imbanaco, Cali, Colombia
A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01201265
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Completed
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1155
- Registration Number
- NCT01200225
A Study of RO5310074 in Patients With Psoriatic Arthritis
Phase 1
Completed
- Conditions
- Arthritis, Psoriatic
- Interventions
- Drug: PlaceboDrug: RO5310074
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT01199809
A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT01197911
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT01196052
A Study of the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of Single Dose RO5313534 in Healthy Volunteers, and the Effect of RO5313534 on Safety and Tolerability of Steady State Memantine
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01196065
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)
Terminated
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1240
- Registration Number
- NCT01196780
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Phase 4
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT01196078
A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT01195272
Β© Copyright 2025. All Rights Reserved by MedPath